39results about How to "Realize non-invasive testing" patented technology

The invention discloses a detection method and an application of lung cancer genes. According to the application, the detection method comprises the following steps: constructing a cfDNA library, and conducting hybrid capturing on the cfDNA library by virtue of 12659 probes which are designed in accordance with 105 lung cancer associated genes, sequencing the genes by virtue of a computer, and conducting data analysis on a sequencing result, so that comprehensive and accurate lung cancer gene information is obtained. According to the application, the detection method can implement with a small amount of peripheral blood, so that noninvasive detection is actually achieved. The detection method disclosed by the invention, by capturing, sequencing and analyzing important lung cancer genes in ctDNA, can be used for screening lung cancer in the early stage; therefore, related medication gene mutation information is provided for patients with the lung cancer, and an important reference is provided for the early diagnosis of the lung cancer, personalized accurate medication guidance, effectiveness evaluation and prognosis dynamic monitoring.

The invention provides a method for building an ALK gene fusion mutation detection library. The method includes the steps of firstly, extracting DNA, and fragmenting the DNA; secondly, building a DNA pre-library; thirdly, cyclizing the DNA; using ALK specific primers to perform PCR amplification, and enriching a target area to generate the final library. The invention further provides a kit for building the ALK gene fusion mutation detection library and a method for detecting ALK gene fusion mutation. The method for building the ALK gene fusion mutation detection library has the advantages that the method targeted at ALK recombination hot spot regions is excellent in sensitivity when being combined with the second-generation high-through sequencing technology, and plasma DNA or tissue DNA can be used as the initial material to accurately detect the information of ALK gene fusion mutation; in addition, when the plasma DNA is used as the initial material, noninvasive detection of ALK gene fusion mutation and crizotinib drug-resistant mutation is achieved.

The invention provides a skin image information processing-based age testing method. According to the invention, based on the mining of age-related changing texture information of skin surface, a novel, simple and noninvasive age estimation method is provided for medical workers. According to the skin image information processing-based age testing method, a skin image of the middle segment of the ventral side of a forearm is acquired in a noninvasive manner; preprocessing and feature extraction are performed on the acquired skin image, so that relevant parameters of skin grooves and skin ridges are obtained; and the correlation between the parameters and the age is analyzed by using a statistical method, so that the mathematical model of age inference can be obtained. As indicated by statistical results, the skin texture parameters obtained through adopting the method all have high linear correlation with the edge; and when the edge inference model which is obtained through statistical analysis is tested, high accuracy can be obtained. Thus, the effectiveness of the method in age inference can be proved, and cost required by the method is low, and therefore, the method can be prospectively used for objective inference of medical age.

The present invention provides a multi-gene detection primer probe set for early diagnosis, screening or detection of digestive tract tumors, and belongs to the field of biomedicine. The primer probeset comprises at least two groups selected from the following five groups of primers and probes: (1) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SDC2 gene; (2) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SFRRP2 gene; (3) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated SEP9 gene; (4) a forwardprimer, a reverse primer, a Blocker primer and a probe of a methylated CADM1 gene; and (5) a forward primer, a reverse primer, a Blocker primer and a probe of a methylated PAX1 gene. The multi-gene detection primer probe set simultaneously detects two or more methylated markers, is high in sensitivity, good in specificity, convenient in detection, and low in cost, and can be used for early screening and auxiliary diagnosis of the digestive tract tumors.

The invention relates to a prostate cancer early diagnosis or prognosis evaluation marker lncRNA malat1 and application thereof. The marker is an exosome-derived long-chain non-coding RNA (lncRNA) malat1, has a good indicating effect on the early diagnosis of a prostate cancer, can realize the non-invasive detection on the prostate cancer and has higher sensitivity and specificity when being compared with a conventional prostate cancer non-invasive detection method, thereby clinically avoiding the unnecessary puncture biopsy for prostate cancer suspected patients. In addition, the marker alsohas a good prediction effect on the prognosis of the prostate cancer and favorably guides the recurrence monitoring and the early clinical intervention of the patients.

The invention discloses a noninvasive blood sugar detection device based on a raman scattering spectrum. The noninvasive blood sugar detection device based on a raman scattering spectrum comprises a semiconductor laser, an optical fiber beam splitter, an optical fiber probe, a light filter, a raman spectrometer, a first circuit switch, a second circuit switch, a phase locking amplifier, a heart rate measuring apparatus and a computer. According to the noninvasive blood sugar detection device based on a raman scattering spectrum disclosed by the invention, raman scattering light contains rich molecular vibration information, the characteristics that the raman scattering spectrum having different molecules has different features are utilized, the raman scattering spectrum is used for recognizing molecules; and through the relative value of a glucose characteristic peak at the position of 1125cm-1 in the raman scattering spectrum in pure blood to the hemoglobin characteristic peak value at the position of 1549cm-1, and real-time human body blood sugar concentration data measured by a blood sugar biochemistry instrument, a standard straight line L of the relationship between the relative peak value of the glucose characteristic peak at the position of 1125cm-1 and the human body blood sugar concentration is constructed, and finally noninvasive real-time detection of the human bodyblood sugar is realized. The noninvasive blood sugar detection device disclosed by the invention has the advantages of being high in precision, pollution-free, harmless to human bodies and the like, and has great application prospects in the field of biological noninvasive detection.

The invention discloses a deafness gene detection kit. The deafness gene detection kit is suitable for detection of a GJB3 gene locus, a GJB2 gene locus, a mitochondrial DNA locus and a SLC26A4 gene locus. The detection kit comprises primers of GF1 to GF9 and GR1 to GR9. The probes comprise sequence probes P1 to P18. Each sequence probe comprises a wild-type probe and a mutant probe. The deafnessgene detection kit realizes non-invasive prenatal detection for pregnant women and early finds deaf children.

The invention discloses a kit for detecting benign or malignant pulmonary nodules and an application thereof. The kit comprises the following components: (A) a detection reagent, wherein the detection reagent is magnetic beads treated by streptavidin; (B) a first-type detection component which is an independently designed adapter, wherein the sequence of partial nucleotide is shown in SEQ ID NO:1; (C) a second-type detection component, wherein the detection component is a primer designed according to 358 genes related to the pulmonary nodules, and the sequence of partial primers is shown in SEQ ID NO:2 and SEQ ID NO:3; and (D) a third-type detection component, wherein the third-type detection component is 75642 capture probes designed according to 358 genes related to the pulmonary nodules, and the sequence of partial probes is shown in SEQ ID NO:4 and SEQ ID NO:5. The kit can be used for screening early diseases of lung cancer and discriminating the benign and malignant pulmonary nodules.

The invention provides a bladder cancer detection kit and application thereof. By detecting expression of at least one of miR-423-5p, miR-203-3p, miR-21-5p and miR-30b-5p in exosomes from tumors, thekit and system can be used for detecting tumors by utilizing urine which is a biological sample and are high in stability and accurate in quantification. The kit is rapid, low in cost, high in accuracy and high in sensitivity.

The invention discloses an ultrasonic cross-scale and multi-parameter detection imaging platform and method, and belongs to the technical field of ultrasonic imaging. Comprising the following steps: acquiring channel data, ultrasonic image data and video data which are not subjected to beam forming; performing beam forming on the channel data to obtain radio frequency data; realizing passive acoustic imaging by using channel data according to frame number selection; using radio frequency data to obtain cross-scale ultrasonic structure images: super-resolution imaging, multi-mechanical parameter imaging and microbubble subharmonic blood pressure imaging; obtaining the ultrasonic three-dimensional image by processing an ultrasonic image, video data, passive acoustic imaging and a cross-scale ultrasonic structure image based on a three-dimensional reconstruction and visualization technology. The platform comprises an ultrasonic signal acquisition control sub-platform, a cross-scale multimode imaging sub-platform and a three-dimensional reconstruction sub-platform. According to the invention, multi-mode imaging based on ultrasonic cross-scale and multi-parameter detection is realized.

The invention provides a detection method of a guide wire-free FFR, a guide wire-free IMR and a guide wire-free CFR. The method comprises the following steps: acquiring a 2D coronary image of a blood vessel to be measured; constructing a 3D blood vessel model according to the 2D coronary artery image; acquiring the central arterial pressure of the blood vessel to be measured by using a non-invasive measurement method; constructing a 3D coronary CFD model of the blood vessel to be measured at least according to the 3D blood vessel model and the central arterial pressure; and calculating a guidewire-free CFR, a guidewire-free FFR and a guidewire-free IMR according to the 3D coronary CFD model. The non-invasive detection of CFR, FFR and IMR by adopting a DSA image auxiliary technology is realized.

The invention provides a device for noninvasively detecting indocyanine green content in bodies. The device includes a laser emitting device that can emit single wavelength or multi-wavelength with the wavelength of 805 nm, and photoacoustic signal detection and conversion devices; and preferably, the device also includes an ultrasonic positioning device, and the ultrasonic positioning device canaccurately detect the indocyanine green content in a blood vessel at a specific position without being disturbed by other tissue. Through the device, the noninvasive detection on the indocyanine greencontent in blood can be realized; rapid assessment on hepatic functional reserve can be realized; and therefore, the device has good commercial prospects.

The invention provides a noninvasive blood glucose screening system based on a gas discharge imaging technology. The system comprises a GDV instrument, a meridian energy parameter acquisition module, a disease parameter and meridian energy parameter correlation analysis module, a mathematical model establishment module and a diabetes attack score determination module. The system is used for screening out meridian energy parameters related to diabetes diagnosis according to a fingertip glow image of a user, establishing a mathematical model according to the meridian energy parameters, and obtaining a diabetes attack score cut-point according to the meridian energy parameters related to diabetes diagnosis and the mathematical model, so as to determine the risk degree of the user suffering from diabetes according to the diabetes attack score cut-point. According to the noninvasive blood glucose screening system based on the gas discharge imaging technology, the diabetes attack risk value and corresponding conditioning suggestions can be obtained by collecting two photos of fingers of the left hand and the right hand of the user, the coverage rate of diabetes screening can be increased, and part of hidden or early diabetes patients can be found in time.

One or more embodiments of the invention provide a blood glucose monitoring device, which is characterized by comprising a device main body, a parameter detection system and a blood glucose calculation system are arranged in the device main body, wherein the parameter detection system detects various physical sign parameters of a detected person and sends the parameters to the blood glucose calculation system, and the blood glucose calculation system calculates a blood glucose concentration value according to the parameters sent by the parameter detection system. The noninvasive detection can be achieved, convenience and rapidness are achieved, and pain of a detected person is relieved.

The invention discloses application of an ST3GAL6-AS1 gene as well as a specific primer pair and a kit, and the specific primer pair aiming at the ST3GAL6-AS1 gene comprises an upstream primer and a downstream primer; the nucleotide sequence of the upstream primer is as shown in SEQ ID No. 1; and the nucleotide sequence of the downstream primer is as shown in SEQ ID No.2. The kit comprises a specific primer pair aiming at the ST3GAL6-AS1 gene. The ST3GAL6-AS1 gene is used as a detection marker of MM and MRD for the first time and is used for detecting multiple myeloma and multiple myeloma residues, high sensitivity and high specificity are achieved, and noninvasive detection can be achieved; and the kit disclosed by the invention not only can be applied to qualitative detection of MM and MRD, but also can be used for quantitatively determining the invasion and migration capabilities of tumor cells in the body of a patient through comparison with a reference gene.